Back to results
US 2026/0295016 A1Published application
Neurotrauma treatment
AssigneeEcole Polytechnique Federale De Lausanne (Epfl)
InventorsGregoire COURTINE, Mark ANDERSON, Jordan SQUAIR, Bernard SCHNEIDER
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutical compositions, combinations and vectors, such as expression vectors, as well as use thereof in a method for central nervous system repair after neurotrauma, such as spinal cord injury (SCI) or stroke and in a method for regenerating spinal cord or brain neurons within a subject having a spinal cord injury (SCI), stroke or other neurotraumatic conditions.
Claims22
A pharmaceutical combination comprising:
- i) a first agent comprising exogenous nucleic acid encoding an osteopontin (Spp1) polypeptide as set forth in SEQ ID NO:
- 1 or SEQ ID NO:
- 8, insulin-like growth factor 1 (Igf1) polypeptide as set forth in SEQ ID NO:
- 2, and ciliary-derived neurotrophic factor (Cntf) polypeptide as set forth in SEQ ID NO:
- 3 or SEQ ID NO:
- 9;
- and/or
- ii) a second agent comprising exogenous nucleic acid encoding a fibroblast growth factor 2 (FGF2) polypeptide as set forth in SEQ ID NO:
- 4 or SEQ ID NO:
- 10, epidermal growth factor (EGF) polypeptide as set forth in SEQ ID NO:
- 5 or SEQ ID NO:
- 11, and a glial-derived neurotrophic factor (GDNF) polypeptide as set forth in SEQ ID NO:
- 6;
- wherein, when both present, said first and second agents are administered sequentially or simultaneously, and
- wherein said first and second agents provide sustained expression and secretion of effective amounts of said polypeptides during at least 3 days.
12 more elements
Dependencies are inferred from the claim text.